Elanco Animal Health IncNYSE:ELAN
- LAST PRICE18.2400
- TODAY'S CHANGE (%)0.0100 (0.0549%)
- Bid / Lots18.2400/ 3
- Ask / Lots18.2500/ 8
- Open / Previous Close18.2100 / 18.2300
- Day Range
- 52 Week Range
- Volume387,666
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ELAN |
|---|---|---|
| 09:32 ET | 62127 | 18.25 |
| 09:34 ET | 5000 | 18.23 |
| 09:36 ET | 1800 | 18.25 |
| 09:38 ET | 1823 | 18.31 |
| 09:39 ET | 503 | 18.4 |
| 09:41 ET | 2824 | 18.35 |
| 09:43 ET | 13200 | 18.285 |
| 09:45 ET | 4919 | 18.22 |
| 09:48 ET | 2100 | 18.24 |
| 09:50 ET | 2059 | 18.18 |
| 09:52 ET | 4336 | 18.19 |
| 09:54 ET | 8652 | 18.16 |
| 09:56 ET | 2010 | 18.15 |
| 09:57 ET | 1529 | 18.16 |
| 09:59 ET | 18583 | 18.15 |
| 10:01 ET | 4706 | 18.145 |
| 10:03 ET | 4759 | 18.165 |
| 10:06 ET | 15938 | 18.135 |
| 10:08 ET | 3070 | 18.17 |
| 10:10 ET | 3242 | 18.175 |
| 10:12 ET | 7425 | 18.175 |
| 10:14 ET | 6889 | 18.2 |
| 10:15 ET | 8464 | 18.19 |
| 10:17 ET | 3229 | 18.215 |
| 10:19 ET | 10387 | 18.245 |
| 10:21 ET | 29091 | 18.26 |
| 10:24 ET | 1900 | 18.28 |
| 10:26 ET | 6181 | 18.29 |
| 10:28 ET | 5522 | 18.2843 |
| 10:30 ET | 4115 | 18.28 |
| 10:32 ET | 5867 | 18.27 |
| 10:33 ET | 21435 | 18.29 |
| 10:35 ET | 10828 | 18.28 |
| 10:37 ET | 9792 | 18.285 |
| 10:39 ET | 8317 | 18.31 |
| 10:42 ET | 3904 | 18.29 |
| 10:44 ET | 9001 | 18.29 |
| 10:46 ET | 3307 | 18.3 |
| 10:48 ET | 2973 | 18.29 |
| 10:50 ET | 1509 | 18.295 |
| 10:51 ET | 7765 | 18.235 |
| 10:53 ET | 2594 | 18.24 |
Jun 6, 2024
Elanco to Participate in Goldman Sachs 45th Annual Global Healthcare Conference, from 8:00AM ET on Thursday Jun 06, 2024 by Dow Jones
8:00AM ET on Thursday Jun 06, 2024 by Dow Jones
May 28, 2024
Elanco Announces FDA Has Completed Review of Bovaer(R), First-in-Class Methane-Reducing Feed Ingredient, for U.S. Dairy Industry, from 7:30PM ET on Tuesday May 28, 2024 by Dow Jones
7:30PM ET on Tuesday May 28, 2024 by Dow JonesElanco Announces FDA Has Completed Review of Bovaer(R), First-in-Class Methane-Reducing Feed Ingredient, for U.S. Dairy Industry, from 6:27AM ET on Tuesday May 28, 2024 by Dow Jones
6:27AM ET on Tuesday May 28, 2024 by Dow Jones
May 21, 2024
Elanco to Participate in Stifel 2024 Jaws and Paws Conference, from 8:00AM ET on Tuesday May 21, 2024 by Dow Jones
8:00AM ET on Tuesday May 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Elanco Animal Health Inc | 9.0B | -6.9x | --- |
PetIQ Inc | 656.0M | 103.5x | --- |
Phibro Animal Health Corp | 697.9M | 53.3x | -13.61% |
Supernus Pharmaceuticals Inc | 1.4B | -93.1x | -59.02% |
Eagle Pharmaceuticals Inc | 52.7M | 4.3x | -4.75% |
Shengtai Pharmaceutical Inc | 10.0 | 0.0x | --- |
Company Information
Elanco Animal Health Incorporated is an animal health company. The Company is focused in delivering products and services to prevent and treat disease in farm animals and pets. Its portfolio serves animals across its core species consisting of dogs, cats and cattle, poultry, swine, sheep and aqua. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, poultry, and aquaculture. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.
Contact Information
- Headquarters
- 2500 Innovation Way NGREENFIELD, IN, United States 46140-9163
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Lawrence Kurzius
- President, Chief Executive Officer, Director
- Jeffrey Simmons
- Chief Financial Officer, Executive Vice President
- Todd Young
- Executive Vice President, General Counsel, Company Secretary
- Shiv O'Neill
- Executive Vice President, Human Resources, Corporate Communications and Administration
- David Kinard
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.0B |
|---|---|
Revenue (TTM) | $4.4B |
Shares Outstanding | 494.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.45 |
EPS | $-2.64 |
Book Value | $12.63 |
P/E Ratio | -6.9x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -21.47% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
